MariMed Inc. (MRMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MariMed Inc. (MRMD) trades at $0.077 with AI Score 46/100 (Grade C). MariMed Inc. is a prominent player in the cannabis industry, focusing on the cultivation and sale of medicinal and adult-use cannabis products. Market cap: $30.7M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for MRMD: MRMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MRMD: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MariMed Inc. (MRMD) Healthcare & Pipeline Overview
MariMed Inc. is a leading cannabis company specializing in the cultivation, production, and distribution of a wide range of medicinal and adult-use cannabis products, leveraging a strong brand portfolio and operational expertise across multiple states.
What Is the Investment Thesis for MRMD?
MariMed Inc. presents a unique opportunity in the cannabis sector, driven by its established brand portfolio and diverse product offerings. With a market capitalization of $30.7M and a gross margin of 36.0%, the company is positioned to capitalize on the growing demand for cannabis products. Key growth catalysts include the expansion of its product lines and the ongoing legalization of cannabis in various states, which could significantly enhance market penetration. However, the company faces risks associated with its current profit margin of -7.8%, necessitating close monitoring of its path to profitability. The evolving regulatory landscape also poses challenges that could impact operational efficiency and market access. Investors should evaluate these factors to assess MariMed's long-term viability in the competitive cannabis market.
Based on FMP financials and quantitative analysis
MRMD Key Highlights
Market capitalization of $30.7M, indicating a small-cap status in the cannabis sector.
- Gross margin of 36.0%, reflecting effective cost management in product offerings.
- Profit margin of -7.8%, highlighting the need for operational improvements.
- A workforce of 715 employees, showcasing the company's operational scale.
- Beta of 1.31, indicating higher volatility compared to the broader market.
Who Are MRMD's Competitors?
MRMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CURLF Curaleaf Holdings, Inc. | $9.60 | -2.34% | $2.54B | 53 |
| GTBIF Green Thumb Industries Inc. | $7.51 | -1.44% | $1.64B | 57 |
| CRON Cronos Group Inc. | $3.22 | -2.13% | $1.20B | 62 |
| APHA APHA | $15.27 | -1.04% | 56 | |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRMD's Key Strengths?
Diverse product portfolio catering to various consumer needs.
- Established brand recognition in the cannabis industry.
- Operational scale with 715 employees enhancing production capabilities.
- Strategic licensing agreements allowing for rapid market expansion.
What Are MRMD's Weaknesses?
Current profit margin of -7.8% indicating operational challenges.
- Exposure to regulatory risks in the evolving cannabis landscape.
- Limited international market presence compared to larger competitors.
- Dependence on U.S. market conditions for growth.
What Are the Key Risks for MRMD?
Financial-distress signal — its Altman Z-Score of -0.08 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-23.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What Are the Growth Opportunities for MRMD?
- Growth opportunity 1: MariMed's expansion into new therapeutic areas, particularly in states where cannabis has recently been legalized, presents a significant growth driver. With the U.S. cannabis market projected to grow at a CAGR of 21% through 2025, MariMed can leverage its established brands to capture new customers in these emerging markets. The company's strategic licensing agreements also allow for rapid scaling without the need for extensive capital investment.
- Growth opportunity 2: The increasing consumer demand for CBD products offers a lucrative avenue for MariMed. MariMed's Florance brand is well-positioned to capitalize on this trend, catering to health-conscious consumers seeking natural alternatives. Expanding the product line within this segment could further enhance revenue streams.
- Growth opportunity 3: MariMed's focus on product innovation, particularly in cannabis-infused edibles and beverages, aligns with current consumer preferences for convenient and enjoyable consumption methods. The edibles market is projected to grow at a CAGR of 18% through 2025. By introducing new flavors and formulations under its Kalm Fusion and Bubby's Baked brands, MariMed can attract a broader customer base and increase market penetration.
- Growth opportunity 4: Strategic partnerships and collaborations with other cannabis companies can enhance MariMed's market presence and operational capabilities. By leveraging synergies with established players, MariMed can expand its distribution channels and improve supply chain efficiency. This collaborative approach is essential in a rapidly evolving industry where agility and adaptability are crucial for success.
- Growth opportunity 5: The ongoing trend towards sustainability and eco-friendly practices in the cannabis industry presents an opportunity for MariMed to differentiate itself. By adopting sustainable cultivation and production methods, the company can appeal to environmentally conscious consumers and enhance its brand reputation. This focus on sustainability can also lead to cost savings and operational efficiencies in the long run.
What Threats Does MRMD Face?
- Evolving regulatory landscape posing compliance challenges.
- Intense competition from larger, established cannabis companies.
- Market volatility affecting pricing and demand for cannabis products.
- Potential changes in public perception and acceptance of cannabis use.
What Are MRMD's Competitive Advantages?
- Established brand portfolio with recognized names in the cannabis sector.
- Diverse product offerings catering to various consumer preferences.
- Operational expertise in cannabis cultivation and production.
- Strategic licensing agreements enhancing market reach without heavy capital investment.
- Strong focus on innovation and product development to stay ahead of competitors.
What Does MRMD Do?
Founded in 2011, MariMed Inc. is headquartered in Norwood, Massachusetts, and operates within the rapidly evolving cannabis industry. The company specializes in the cultivation, production, and sale of both medicinal and adult-use cannabis items throughout the United States and internationally. MariMed's diverse product portfolio includes cannabis flowers and concentrates marketed under the Nature's Heritage brand. Additionally, the company offers a variety of infused goods such as chewable tablets and powdered drink mixes under the Kalm Fusion label, natural fruit chews known as Betty's Eddies, and a line of baked treats like brownies and cookies available through Bubby's Baked. Furthermore, MariMed develops cannabidiol (CBD) products under the Florance brand. Beyond its proprietary offerings, the company licenses its various brands and product formulations to others and leases facilities designed for cannabis operations, allowing for a broader market reach. Over the years, MariMed has established itself as a key player in the cannabis sector, capitalizing on the growing acceptance and legalization of cannabis products across various states. With a workforce of 715 employees, MariMed continues to innovate and expand its product lines to meet consumer demand in this competitive industry.
What Products and Services Does MRMD Offer?
- Cultivates and produces cannabis flowers and concentrates.
- Offers a range of infused cannabis products, including edibles and beverages.
- Develops and sells CBD products under the Florance brand.
- Licenses its brands and product formulations to other companies.
- Operates dispensaries and production facilities across multiple states.
- Focuses on innovation and product development to meet consumer demand.
How Does MRMD Make Money?
- Generates revenue through the sale of cannabis products, including flowers, edibles, and concentrates.
- Licenses its brands and product formulations to third parties for additional income.
- Leases facilities designed for cannabis operations to other businesses.
- Engages in direct-to-consumer sales through its dispensaries.
- Expands product offerings to capture emerging market trends and consumer preferences.
What Industry Does MRMD Operate In?
The cannabis industry has experienced significant growth in recent years, driven by increasing legalization and acceptance of both medicinal and recreational cannabis products. Amidst a competitive landscape, MariMed's established brand portfolio and operational expertise position it favorably to capture market share. The growing trend towards cannabis-infused products and wellness solutions further supports the company's growth trajectory, although it must navigate regulatory challenges and market volatility.
Who Are MRMD's Key Customers?
- Medicinal cannabis patients seeking therapeutic products.
- Adult consumers purchasing recreational cannabis items.
- Health-conscious individuals interested in CBD products.
- Retailers and dispensaries looking for licensed cannabis products.
- Businesses seeking to lease cannabis production facilities.
Forward Outlook
Wall Street analysts project MariMed Inc. revenue of about $161.0M for fiscal 2026, with EPS near $-0.05.
Financial Health
MariMed Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.08 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for MariMed Inc. stands at -23.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 20.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.5%, the inverse of the P/E and a quick read on earnings relative to price.
MariMed Inc. (MRMD) Valuation Context
Valued at $30.7M, MRMD is classified as a micro-cap stock. Relative to its peer group, MRMD's quantitative score of 46/100 is below the peer average of 58/100.
Company Profile
MariMed Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Norwood, US. The company is led by CEO Jon R. Levine. MRMD has traded publicly since 2012.
MRMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio catering to various consumer needs.
- Established brand recognition in the cannabis industry.
- Operational scale with 715 employees enhancing production capabilities.
- Strategic licensing agreements allowing for rapid market expansion.
Bear Case
- Current profit margin of -7.8% indicating operational challenges.
- Exposure to regulatory risks in the evolving cannabis landscape.
- Limited international market presence compared to larger competitors.
- Dependence on U.S. market conditions for growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MRMD Latest News
No recent news available for MRMD.
MRMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRMD.
Price Targets
Wall Street price target analysis for MRMD.
MRMD MoonshotScore
What does this score mean?
The MoonshotScore rates MRMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
MRMD OTC Market Information
MRMD trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About MRMD (Healthcare)
What does the AI Score mean for MRMD?
MRMD holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. MariMed Inc. is a prominent player in the cannabis industry, focusing on the cultivation and sale of medicinal and adult-use cannabis products. Established in 2011, the company has developed a …
What are the key factors to evaluate for MRMD?
MariMed Inc. (MRMD) holds an AI score of 46/100 (low). presents a unique opportunity in the cannabis sector, driven by its established brand portfolio and diverse product offerings. Not financial advice.
How frequently does MRMD data refresh on this page?
MRMD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MRMD's recent stock price performance?
MariMed Inc. (MRMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio catering to various consumer needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRMD overvalued or undervalued right now?
MariMed Inc. (MRMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MRMD before investing?
Before investing in MariMed Inc. (MRMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MRMD to a portfolio?
Key strength of MariMed Inc. (MRMD): Diverse product portfolio catering to various consumer needs. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of MRMD?
Yes, most major brokerages offer fractional shares of MariMed Inc. (MRMD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track MRMD's earnings and financial reports?
MariMed Inc. (MRMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for MRMD earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.